Article
Medicine, General & Internal
Athimalaipet Ramanan, Pierre Quartier, Nami Okamoto, Ivan Foeldvari, Alberto Spindler, Sarka Fingerhutova, Jordi Anton, Zhongkai Wang, Gabriella Meszaros, Joana Araujo, Ran Liao, Stuart Keller
Summary: Baricitinib demonstrated good efficacy and acceptable safety in the treatment of polyarticular juvenile idiopathic arthritis, extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis, and juvenile psoriatic arthritis.
Article
Rheumatology
C. Bava, F. Mongelli, A. Pistorio, M. Bertamino, G. Bracciolini, S. Dalpra, S. Davi, S. Lanni, V Muratore, S. Pederzoli, S. Rosina, B. Schiappapietra, C. Suffia, G. C. Varnier, S. Verazza, G. Giancane, A. Consolaro, A. Ravelli
Summary: The study aimed to investigate the frequency of arthritis flare and factors affecting occurrence of flare in children with JIA who achieved inactive disease with MTX monotherapy. Results showed that 78.3% of patients experienced arthritis flare after a median of 1.6 years, with most flare episodes not treated with biologic therapy. The risk of flare was independent of withdrawal strategy, and majority of patients who had MTX withdrawn experienced flare.
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY
(2021)
Review
Rheumatology
Claas H. Hinze, Dirk Foell, Christoph Kessel
Summary: Systemic juvenile idiopathic arthritis (sJIA) is a disease characterized by severe systemic inflammation and arthritis. It poses challenges to rheumatologists treating pediatric and adult patients worldwide. Although treatment plans exist for classic sJIA, there is still a lack of clear treatment approaches for early sJIA without arthritis and complicated sJIA.
NATURE REVIEWS RHEUMATOLOGY
(2023)
Article
Pediatrics
Tiina Levalampi, Johanna Karki, Katariina Rebane, Paula Vahasalo, Merja Malin, Liisa Kroger, Minna-Maija Gronlund, Maria Backstrom, Heini Pohjankoski, Hannu Kautiainen, Sakari Jokiranta, Kristiina Aalto
Summary: This study investigated the effects of concomitant methotrexate on serum etanercept concentration and clinical response in children with juvenile idiopathic arthritis. The results demonstrated that methotrexate had no impact on etanercept concentration or clinical response, and a significant correlation was observed between etanercept dose and concentration.
PEDIATRIC RHEUMATOLOGY
(2023)
Article
Rheumatology
Jelena Vojinovic, Ivan Foeldvari, Joke Dehoorne, Violeta Panaviene, Gordana Susic, Gerd Horneff, Valda Stanevicha, Katarzyna Kobusinska, Zbigniew Zuber, Bogna Dobrzyniecka, Jonathan Akikusa, Tadej Avcin, Cecilia Borlenghi, Edmund Arthur, Svitlana Y. Tatulych, Chuanbo Zang, Vassilis Tsekouras, Bonnie Vlahos, Alberto Martini, Nicolino Ruperto
Summary: CLIPPER2 is an 8-year study on the safety and efficacy of etanercept in patients with juvenile idiopathic arthritis (JIA). The study found that etanercept treatment was well tolerated and effective in these patients.
Article
Rheumatology
Joeri W. van Straalen, Roline M. Krol, Gabriella Giancane, Violeta Panaviene, Laura Marinela Ailioaie, Pavla Dolezalova, Marco Cattalini, Gordana Susic, Flavio R. Sztajnbok, Despoina Maritsi, Tamas Constantin, Sujata Sawhney, Marite Rygg, Sheila Knupp Oliveira, Ellen Berit Nordal, Claudia Saad-Magalhaes, Nadina Rubio-Perez, Marija Jelusic, Sytze de Roock, Nico M. Wulffraat, Nicolino Ruperto, Joost F. Swart
Summary: IBD development in JIA is associated with enthesitis-related arthritis and a family history of autoimmune disease. An increased incidence of IBD was observed with etanercept therapy regardless of concomitant methotrexate use.
Article
Pediatrics
Federica Filosco, Alessandro Giallongo, Salvatore Leonardi, Venera Tomaselli, Patrizia Barone
Summary: This study aimed to assess predictors of remission in children with juvenile idiopathic arthritis (JIA) treated with intra-articular corticosteroid injection (IACI) as monotherapy or in combination with methotrexate. The results showed that early IACI is a strong predictor of remission.
MINERVA PEDIATRICS
(2023)
Review
Medicine, General & Internal
Pierre Quartier
Summary: Children with early onset juvenile idiopathic arthritis, especially with positive antinuclear antibodies, may develop chronic anterior uveitis, which requires regular slit lamp examination and prompt treatment. Therapy options range from local steroid treatment to systemic immunomodulatory therapy, tailored to individual patient needs, with involvement of expert ophthalmologists and pediatricians. Treatment should not be easily interrupted and may need to be intensified in certain cases for optimal disease control.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Pediatrics
Anders Oman, Johan Dicksved, Lars Engstrand, Lillemor Berntson
Summary: This study found that treatment with methotrexate or etanercept in children with juvenile idiopathic arthritis did not significantly alter the composition or function of the fecal microbiota, suggesting that these changes are not related to the therapeutic effects of the medications.
PEDIATRIC RHEUMATOLOGY
(2021)
Article
Pediatrics
Xuefeng Xu, Xiaohui Liu, Wenjie Zheng, Jihong Xiao, Xiaozhong Li, Ling Wu, Lixia Zou, Qian Ouyang, Yaoyao Shangguan, Kezhao Lin, Xiaomei Dai, Yuanling Chen, Yiping Xu, Jianqiang Wu, Meiping Lu
Summary: This study suggests that the combination of rhTNFR-Fc and MTX significantly improves symptoms and disease activity in children with JIA.
FRONTIERS IN PEDIATRICS
(2022)
Article
Rheumatology
Alessandra Alongi, Gabriella Giancane, Roberta Naddei, Valentina Natoli, Francesca Ridella, Marco Burrone, Silvia Rosina, Gaelle Chedeville, Ekaterina Alexeeva, Gerd Horneff, Ivan Foeldvari, Giovanni Filocamo, Tamas Constantin, Nicolino Ruperto, Angelo Ravelli, Alessandro Consolaro
Summary: This study aimed to investigate the frequency of a global assessment of disease activity (PhGA) >0 and an active joint count (AJC)=0 in children with juvenile idiopathic arthritis (JIA) and search for determinants of divergence between the two measures. The study found that many pediatric rheumatologists did not mark a score of 0 for patients who they found not to have active joints, and the presence of pain in joints not meeting the definition of active joint used in JIA was the main determinant of this phenomenon.
Article
Pharmacology & Pharmacy
Ryan Sol Funk, Mara L. Becker
Summary: Variability in methotrexate efficacy poses a challenge in treating juvenile idiopathic arthritis. This study aimed to explore the impact of methotrexate on plasma metabolome and identify metabolic biomarkers of efficacy in children with JIA. The research revealed diverse metabolic changes following methotrexate initiation, including metabolites associated with microbial metabolism and exogenous sources.
FRONTIERS IN PHARMACOLOGY
(2021)
Review
Medicine, General & Internal
William D. Renton, Jennifer Jung, Alan G. Palestine
Summary: The study evaluated the effectiveness and safety of tumor necrosis factor (TNF) inhibitors for the treatment of juvenile idiopathic arthritis associated uveitis (JIA-U) with 134 participants. The findings suggest that adalimumab appears to increase the likelihood of treatment success and decrease the likelihood of treatment failure when compared with placebo, while the evidence on etanercept is less conclusive. Further research is needed.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS
(2022)
Article
Biology
Artem K. Artamonov, Maria A. Kaneva, Natalia A. Gordeeva, Lubov S. Sorokina, Mikhail M. Kostik
Summary: Our study aimed to evaluate the clinical and laboratory features of juvenile idiopathic arthritis (JIA) children with temporomandibular joint (TMJ) arthritis. TMJ arthritis was detected in 43 (5.7%) of our patients and associated with a longer course of the disease, polyarticular JIA category, treatment with systemic corticosteroids, and longer achievement of remission and involvement of cervical spine, hip, and shoulder. Patients with TMJ arthritis require more biologics and have decreased probability of remission achievement.
Article
Rheumatology
Jens Klotsche, Ariane Klein, Martina Niewerth, Paula Hoff, Daniel Windschall, Ivan Foeldvari, Johannes-Peter Haas, Gerd Horneff, Kirsten Minden
Summary: The study confirms the effectiveness of ETA in re-treatment of JIA patients. Data highlight the association of early bDMARD treatment with a higher rate of inactive disease.
ARTHRITIS RESEARCH & THERAPY
(2021)